Andrew Ko, MD
Professor of Clinical Medicine; Interim Division Chief, Oncology, Division of Hematology/Oncology, UCSF
Cancer Center Program Memberships
Experimental TherapeuticsResearch Summary
My primary clinical and research interests focus on gastrointestinal malignancies, where I have developed and led multiple clinical trials, both within UCSF and across multiple sites nationwide and overseas. I am interested in the development and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to immunotherapies, with a particular emphasis on evaluating these in patients with pancreatic cancer. This work has entailed collaborating with laboratory-based investigators on the correlative/translational science to identify individual patient/tumor characteristics that influence prognosis and response to specific therapies, including both tissue- and blood-based biomarkers. Other university responsibilities include leading the site committee for gastrointestinal cancer-specific clinical trial development at the UCSF HDFCCC and serving as chair of the scientific Protocol Review Committee. Nationally, I have served on the scientific program committee, grants committee, and specialty editorial board for the American Society of Clinical Oncology (ASCO), sit on the editorial board for multiple peer-reviewed oncology journals, and am currently a member of NCI’s Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.Education
Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
Board certified, Internal Medicine, 1998
Board certified, Medical Oncology, 2002
Professional Experience
-
1995-1996
Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine -
1996-1998
Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine -
1998-2001
Stanford University School of Medicine, fellow, Division of Medical Oncology -
2001-present
University of California at San Francisco, Clinical Instructor, Division of Hematology/Oncology -
2003-2009
University of California at San Francisco, Assistant Clinical Professor, Division of Hematology/Oncology -
2009-2018
University of California at San Francisco, Associate Professor of Clinical Medicine, Division of Hematology/ Oncology -
2019-present
University of California, San Francisco, Professor of Clinical Medicine, Division of Hematology/Oncology -
2019-present
University of California, San Francisco, Interim Division Chief, Oncology, Division of Hematology/Oncology
Honors & Awards
- 1987
National Merit Scholarship - 1988
IBM Thomas J. Watson Memorial Scholarship - 1990
Sigma Xi, elected associate member - 1991
Departmental honors and Magna cum laude, Brown University - 1993
Alpha Omega Alpha, student essay competition honoree - 1994
Harry C. Saltzstein Prize in Medical Writing, Johns Hopkins School of Medicine - 1995
Medical Assistance Programs/Reader's Digest International Fellowship - 2000
Amgen National Oncology Fellows' Forum, selected for oral presentation - 2000
American Society of Clinical Oncology, Travel Award (meritorious abstract) - 2001
Digestive Disease Center Collaborative Postdoctoral Fellowship - 2003
UCSF Cancer Center Clinical Investigator Research Program award - 2003
American Society of Clinical Oncology Career Development Award - 2007
Joan Rombauer UCSF Endowed Fellowship - 2008
UCSF Kaiser Award for Excellence in Teaching in the Classroom Setting, nominee - 2011
NCI Cancer Clinical Investigator Team Leadership Award - 2013
UCSF Hematology and Oncology Division Teaching Award
Selected Publications
- Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners BL, Ferguson A, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Jun 26.
View on PubMed - Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87. Ann Oncol. 2020 Jun 04.
View on PubMed - Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients. Oncologist. 2020 May 10.
View on PubMed - Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, Coussens LM, Jaffee EM, Le DT. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clin Cancer Res. 2020 Apr 09.
View on PubMed - Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. Oncologist. 2020 Feb 07.
View on PubMed - Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 01; 31(1):79-87.
View on PubMed - Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2019 12; 42(12):898-902.
View on PubMed - Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779.
View on PubMed - Ko AH, Nakakura EK. Adjuvant Therapy for Ampullary Cancer. JAMA Surg. 2019 Aug 01; 154(8):715.
View on PubMed - Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas. 2019 08; 48(7):927-930.
View on PubMed - Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019 08 01; 111(8):782-794.
View on PubMed - Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502.
View on PubMed - Wu C, Jermakowicz WJ, Chakravorti S, Cajigas I, Sharan AD, Jagid JR, Matias CM, Sperling MR, Buckley R, Ko A, Ojemann JG, Miller JW, Youngerman B, Sheth SA, McKhann GM, Laxton AW, Couture DE, Popli GS, Smith A, Mehta AD, Ho AL, Halpern CH, Englot DJ, Neimat JS, Konrad PE, Neal E, Vale FL, Holloway KL, Air EL, Schwalb J, Dawant BM, D'Haese PF. Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients. Epilepsia. 2019 06; 60(6):1171-1183.
View on PubMed - Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 04; 18(2):241-251.
View on PubMed - Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2019 03; 43(3):334-340.
View on PubMed - Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 03 01; 17(3):202-210.
View on PubMed - Munigala S, Gardner TB, O'Reilly EM, Castillo CF, Ko AH, Pleskow D, Mills JB, Vollmer CM, Searle NA, Alsante M, Holt JM, Gelrud A. Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning. Pancreas. 2018 Nov/Dec; 47(10):1256-1261.
View on PubMed - Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr. 2018 Oct; 7(5):406-408.
View on PubMed - Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 11; 211(5):1010-1019.
View on PubMed - Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 05 10; 4(5):e180013.
View on PubMed